Почетна › Рак на дојка › Џорџија › Atlanta
Клинички испитувања за Рак на дојка во Atlanta, GA
Една студија за Рак на дојка бара учесници на локација во или блиску до Atlanta. Отворете ја за да видите кој може да учествува и како да го контактирате тимот.
Официјален текст на студијата (англиски)
Барате учесници за студија? Истакнете ја на врвот од оваа страница — $99 за 30 дена →
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Се регрутираФаза 3
- Atlanta Cancer Care - Northside Hospital, Atlanta
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Се регрутираНабљудувачка студијаДобредојдени се здрави волонтери
- Atlanta VA Medical Center, Decatur · на 6 милји
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Се регрутираФаза 2
- Winship Cancer Institute, Emory University, Atlanta
Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
Се регрутираФаза 3
- Emory Proton Therapy Center, Atlanta
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
Се регрутираФаза 3
- Emory University Hospital, Atlanta
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
Се регрутираФаза 3
- Emory University Winship Cancer Institute, Atlanta
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Се регрутираФаза 1
- Emory University School of Medicine - Winship Cancer Institute, Atlanta
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Се регрутираФаза 2
- Winship Cancer Institute, Atlanta
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
Се регрутираФаза 1/2
- Winship Cancer Institute of Emory University, Atlanta
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Се регрутираФаза 3
- Winship Cancer Institute, Atlanta
- Northside Hospital, Atlanta
A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
Се регрутираФаза 2
- Emory University (Data Collection Only), Atlanta
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Се регрутираФаза 1/2
- Winship Cancer Institute of Emory University, Atlanta
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Се регрутираФаза 1
- Emory University, Atlanta
Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
Се регрутираФаза 2
- Emory University, Atlanta
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Се регрутираФаза 3
- Winship Cancer Institute of Emory University, Atlanta
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Се регрутираФаза 3
- Grady Health System, Atlanta
- Emory University Hospital Midtown, Atlanta
- Piedmont Hospital, Atlanta
- и уште 5
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Се регрутираФаза 1
- Emory University - Winship Cancer Institute, Atlanta
Mobile Health Patient Navigation for the Improvement of Screening and the Early Detection of Breast Cancer in Women Accessing Primary Care Clinics in Kenya
Се регрутираДобредојдени се здрави волонтери
- Emory University Hospital/Winship Cancer Institute, Atlanta
FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
Се регрутираФаза 1
- Emory University, Atlanta
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
Се регрутираФаза 2
- Winship Cancer Institute at Emory University, Atlanta
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Се регрутираФаза 2/3
- Northside Hospital, Atlanta
E-Mindfulness Approaches for Living After Breast Cancer
Се регрутираФаза 3
- Grady Health System, Atlanta
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- и уште 2
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Се регрутираФаза 1/2
- Emory University, Atlanta
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Се регрутираФаза 1/2
- Winship Cancer Institute, Emory University, Atlanta
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Се регрутираФаза 1/2
- Winship Cancer Institute, Emory University, Atlanta
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
Се регрутираФаза 2
- GSK Investigational Site, Atlanta
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Се регрутираФаза 3
- Emory University School of Medicine, Atlanta
Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics
Се регрутираДобредојдени се здрави волонтери
- Emory University Hospital/Winship Cancer Institute, Atlanta
Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab
Се регрутираНабљудувачка студијаДобредојдени се здрави волонтери
- Emory University/Winship Cancer Institute, Atlanta
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Се регрутираФаза 2
- Winship Cancer Institute of Emory University, Atlanta
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Се регрутираФаза 3
- Emory University Hospital Midtown, Atlanta
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
Се регрутираФаза 2
- Emory University Winship Cancer Institute, Atlanta
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Се регрутираФаза 3
- Grady Health System, Atlanta
- Emory University Hospital Midtown, Atlanta
- Piedmont Hospital, Atlanta
- и уште 5
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Се регрутираФаза 1/2
- Research Site 111, Atlanta
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Се регрутираФаза 1/2
- Emory Winship Cancer Institute, Atlanta
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Се регрутираНабљудувачка студија
- Northside Hospital, Atlanta
Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
Се регрутираФаза 1
- Emory University, Winship Cancer Institute, Atlanta
Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
Се регрутираФаза 1
- Grady Health System, Atlanta
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- и уште 1
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Се регрутираНабљудувачка студија
- Massive Bio SYNERGY-AI site, Atlanta
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Се регрутираФаза 3
- Emory University Hospital/Winship Cancer Institute, Atlanta
- Northside Hospital, Atlanta
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Се регрутираНабљудувачка студија
- Piedmont Cancer Institute, Atlanta
- Emory University - Winship Cancer Institute, Atlanta
Испитувања за Рак на дојка во други градови
- New York City, NY136 студии
- Houston, TX126 студии
- Boston, MA112 студии
- Nashville, TN81 студија
- Los Angeles, CA73 студии
- Edison, NJ68 студии
- St. Louis, MO64 студии
- Queens, NY64 студии
- Durham, NC64 студии
- Chicago, IL59 студии
- Philadelphia, PA56 студии
- Dallas, TX55 студии
Други студии во Atlanta
- Рак (сите типови)49 студии
- Рак на бели дробови со не-мали клетки47 студии
- Множен миелом42 студии
- Рак на простата33 студии
- Акутна миелоидна леукемија31 студија
- Карцином на јајниците29 студии
- Колоректален карцином29 студии
- Рак на бели дробови29 студии
- Метастатски карцином28 студии
- Голема депресивна нарушување25 студии
- Срцева слабост25 студии
- Сквамозноклеточен карцином на глава и врат24 студии
Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.